SkinBioTherapeutics plc (AIM:SBTX)

London · Delayed Price · Currency is GBP · Price in GBX

6.35

+0.10 (1.60%)

Sep 25, 2026, 12:15 PM GMT

Market Cap	16.20M -62.3%
Revenue (ttm)	5.23M +95.2%
Net Income	-456.41K
EPS	-0.00
Shares Out	259.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,080
Open	6.48
Previous Close	6.25
Day's Range	6.00 - 6.50
52-Week Range	5.00 - 23.00
Beta	0.10
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 3, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 41

Stock Exchange London Stock Exchange AIM

Ticker Symbol SBTX

Full Company Profile

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.

Financial Statements